Medicine
Zimhi 5 mg/0.5 mL injection
Zimhi 5 mg/0.5 mL injection is a prescription medicine containing Naloxone for intramuscular, subcutaneous use, marketed by ZMI Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store ZIMHI in the outer case provided. Store below 77 • F (25 • C)…
Key facts
- Active ingredient (INN)
- Naloxone
- Brand
- Zimhi
- Strength
- 5 mg/0.5 mL
- Dosage form
- Injection
- Route
- Intramuscular, subcutaneous
- Packs
- 2 case of 0.5 mL, 1 case of 0.5 mL
- Marketing authorisation holder
- ZMI Pharma
- Manufacturer
- ZMI Pharma
- Origin register
- US FDA, United States
- Storage
- Store ZIMHI in the outer case provided. Store below 77 • F (25 • C). Excursions permitted up to 104 • F (40 • C). Protect from light. Prior to a medical emergency (during storage), periodically visually inspect ZIMHI through the viewing window on the device.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A06AH04 Naloxone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 January 2022
- Identifiers
- RxCUI 2589612, 2589618DailyMed set ID 523c0909-bff6-4010-988a-53de18b7cb3fNDC 84571-140Application NDA212854
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 case in 1 carton / 1 syringe in 1 case / .5 mL in 1 syringe | 84571-140-02 | ZMI Pharma | 15 January 2022 |
| 1 case in 1 carton / 1 syringe in 1 case / .5 mL in 1 syringe | 84571-140-11 | ZMI Pharma | 15 January 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Naloxone
Clinical summary
Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. MedsAcross supplies Naloxone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NaloxoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Narcan prescribing information (Emergent Devices) · U.S. National Library of Medicine, DailyMed
- Nyxoid: European public assessment report (EPAR) · European Medicines Agency
Need Zimhi 5 mg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.